With the advances of genomics, molecular-targeted therapy like using tyrosine kinase inhibitors (TKIs), which targets the epidermal growth factor receptor (EGFR) mutations, is recommended as first-line system therapy before first-line therapy by National Comprehensive Cancer Network (NCCN) for patients with advanced EGFR-mutant NSCLC (2) and proved to substantially improve the progression-free survival (PFS) compared with conventional chemotherapy (3, 4). Here, EGFR is linked to non-small cell lung carcinoma.